{
    "2020-03-23": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Form 8.3 - Abbvie Plc - Amendment",
                "features": {
                    "keywords": [
                        "Form 8.3",
                        "Amendment"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-03-15",
                "original_text": "Is AbbVie a Good Stock to Buy Amid Coronavirus Uncertainty?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Coronavirus",
                        "Uncertainty"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-03-16",
                "original_text": "The Zacks Analyst Blog Highlights: Macy's, AbbVie, Pfizer and New Residential Investment",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Macy's",
                        "AbbVie",
                        "Pfizer",
                        "Residential",
                        "Investment"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "retail",
                        "real estate"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-04-01",
                "original_text": "Form 8.3 - Abbvie Inc - Amendment",
                "features": {
                    "keywords": [
                        "Form 8.3",
                        "Amendment"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-05-15",
                "original_text": "AbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Positive",
                        "Topline",
                        "Results",
                        "Phase 3",
                        "Trial",
                        "VENCLEXTA",
                        "AML"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-06-10",
                "original_text": "AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Extension",
                        "Expiration",
                        "Date",
                        "Exchange",
                        "Offers",
                        "Allergan",
                        "Notes"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-07-01",
                "original_text": "FORM 8.3 - ABBVIE PLC",
                "features": {
                    "keywords": [
                        "Form 8.3"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-08-15",
                "original_text": "Big deals in limbo spell ‘arb-ageddon’ for hedge funds",
                "features": {
                    "keywords": [
                        "Big",
                        "deals",
                        "limbo",
                        "arb-ageddon",
                        "hedge",
                        "funds"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-09-20",
                "original_text": "AbbVie Stock Falls 3%",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Stock",
                        "Falls"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-10-10",
                "original_text": "AbbVie drops patent rights for Kaletra antiviral treatment",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "drops",
                        "patent",
                        "rights",
                        "Kaletra",
                        "antiviral",
                        "treatment"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}